Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.

- Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;

- Age greater than or equal to 18 years;

- Female participants, post-menarche;

- Clinical diagnosis of vulvovaginal candidiasis, defined as white, fluid or creamy vaginal discharge, in addition to the following findings:

- Itching and one or more of the following signs and symptoms characterized as moderate or severe: vulvar/vaginal erythema, edema, burning, irritation, and excoriation;

- Normal vaginal pH;

- Preparation of KOH or saline from a sample taken from inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or growing yeast.

- Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;

- Participation in a clinical trial in the year prior to this study;

- Pregnancy or risk of pregnancy and lactating patients;

- Known hypersensitivity to any of the formula compounds;

- Virgin participants;

- Postmenopausal participants or with vaginal atrophy;

- Participants with other vaginal infections;

- Participants with recurrent vulvovaginal candidiasis;

- Participants using immunosuppressive drugs;

- Participants diagnosed with serious systemic diseases.